All In Biotech

Drug Trial Radar · NCT07909070

A Study to Investigate the Pharmacokinetics of JMKX003142 in Healthy Participants and Participants With Hepatic Impairment

A Pharmacokinetic Study of JMKX003142 Tablets in Participants With Hepatic Impairment and Participants With Normal Hepatic Function

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Nov 20, 2026

Primary completion

May 30, 2027

Study completion Sep 30, 2027

Sponsor

Lead sponsor
JemincareIndustry
Sponsor type
Industry
Collaborators
Zhejiang Hangyu Pharmaceutical Co., Ltd.
First posted
Nov 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the plasma PK of JMKX003142 following a single dose in participants with mild and moderate hepatic impairment compared to matched healthy participants with normal hepatic function.

Conditions

  • ADPKD (Autosomal Dominant Polycystic Kidney Disease)
  • Renal Edema

Interventions

  • JMKX003142Drug

    Single oral dose of JMKX003142 in participants from all groups

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PK parameter CmaxTime frame: Predose up to 6 days postdose
  2. PK parameters AUC0-tTime frame: Predose up to 6 days postdose
  3. PK parameters AUC0-infTime frame: Predose up to 6 days postdose
  4. PK parameters Cmax, uTime frame: Predose up to 6 days postdose
  5. PK parameters AUC0-t, uTime frame: Predose up to 6 days postdose
  6. PK parameters AUC0-inf, uTime frame: Predose up to 6 days postdose

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.